Comparative effects of methylphenidate and thioridazine in hyperkinetic children. I. Clinical results.

The effects of three pharmacological treatments, methylphenidate hydrochloride, thioridazine hydrochloride, a methylphenidate/thioridazine combination, and placebo were studied in outpatient hyperkinetic children rated hyperactive both in school and at home or clinic. Active treatment lasted 12 weeks; placebo lasted four weeks. Significant clinical improvement was obtained in a variety of settings--all treatments were superior to placebo on ratings filled out by parents, teachers, and clinic staff. Though initially the combination of methylphenidate and thioridazine tended to produce greater clinical improvement, it was not superior to methylphenidate alone after 12 weeks of treatment. Methylphenidate alone and the methylphenidate/thioridazine combination were more effective than thioridazine alone. The salient side effects with methylphenidate treatment were decrease in appetite, difficulty in falling asleep, and increased mood sensitivity. In contrast, thioridazine administration was associated with appetite increase and enuresis.

Relative efficacy of methylphenidate and behavior modification in hyperkinetic children: an interim report.

Children reported to be hyperactive in school and with behavior difficulties at home were randomly assigned to methylphenidate, behavior therapy and placebo, or behavior therapy with methylphenidate for an 8-week period. Rating scales were obtained from teachers and parents. Independent blind observers rated childrens' classroom bheavior on a weekly basis. A behavior therapy program was implemented in the home and at school. Methylphenidate dosage was individualized. Ratings of behavior deviance were significantly reduced by all treatments. However, a significant advantage for the groups receiving methylphenidate was found over the group receiving behavior therapy and placebo. No significant differences between methylphenidate alone and methylphenidate combined with behavior therapy were obtained. Global ratings of improvement done by teachers favored the combined treatment of behavior therapy and methylphenidate over behavior therapy and placebo. No differences among treatments were found in the mothers' global ratings of improvement. The results indicate that though all three treatments were effective, methylphenidate was significantly superior to behavior therapy alone.

Atypical signs of relapse in affective disorders.

The authors have observed that patients with previous well documented evidence of affective illness can have an atypical relapse of depression precipitated by environmental or interpersonal stress. These patients present with complaints centered around problems resulting from current life stress. They deny sad mood and resist the idea that they are having recurrence of depression. It is suggested that the presence of anhedonia be used as a clinical guide to differentiate "understandable" preoccupation with reality problems from emergent depressive relapse. Patients with atypical relapses respond to antidepressants with a disappearance of anhedonia and an ability to place realistic problems in their proper perspective. Cases are presented illustrating this phenomena.